{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:54Z","timestamp":1794047454064,"version":"4.8.0"},"reference-count":29,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Thrombocytopenia occurs frequently in patients with cancer-associated thrombosis (CAT), however prospective evaluation of clinical outcomes following randomization to anticoagulants is limited. The HOKUSAI VTE Cancer study was a randomized, open-label, non-inferiority, phase III trial comparing dalteparin with edoxaban in CAT patients. This post hoc analysis of Hokusai VTE Cancer Study was performed to compare outcomes in patients with platelet count \u2264100x109\/L at one or more specified time points (baseline, 1-month, or 3-month) versus those without thrombocytopenia. Cumulative incidences at 180 days were calculated with death as a competing risk. The primary outcome was major bleeding; secondary outcomes were clinically relevant non-major bleeding (CRNMB), recurrent thrombosis, and survival. The analysis included 1,045 patients with primarily solid tumor malignancies (89%), median age 65 years, and 52% male. The thrombocytopenia group comprised 9.6% (N=101) of the cohort and relative to the non-thrombocytopenia cohort (N=944), experienced significantly higher major bleeding (9.0% vs. 4.0%, sub-distribution hazard ratio [SHR] =2.4; P=0.02) and CRNMB (17.9% vs. 9.6%, SHR=2.0; P=0.01). Thrombocytopenia did not impact recurrent venous thromboembolic event (VTE) (9.8% vs. 7.4%, SHR=1.3; P=0.37) nor overall mortality (21.8% vs. 26.0%, HR=0.9; P=0.48). Major bleeding was higher in patients with thrombocytopenia and gastrointestinal malignancies receiving edoxaban versus dalteparin (16.8% vs. 0; P&lt;0.01) but similar for patients with other malignancies (P=0.30). In patients with hematologic malignances and thrombocytopenia major bleeding was higher for patients receiving dalteparin compared to edoxaban (19.0% vs. 0; P&lt;0.01). Mild thrombocytopenia was associated with a doubling in risk of major hemorrhage in patients receiving anticoagulation for CAT. Bleeding risk for edoxaban and dalteparin varied in gastrointestinal and hematologic malignances in patients with thrombocytopenia (clinicaltrails gov. Identifier: NCT02073682).<\/jats:p>","DOI":"10.3324\/haematol.2023.284192","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:36:26Z","timestamp":1697686586000},"page":"1849-1856","source":"Crossref","is-referenced-by-count":6,"title":["Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer"],"prefix":"10.3324","volume":"109","author":[{"given":"Rushad","family":"Patell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Duggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry R.","family":"Buller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Raskob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Zwicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"62074","doi-asserted-by":"crossref","unstructured":"Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999; 78(5):285-291.","DOI":"10.1097\/00005792-199909000-00001"},{"key":"62075","doi-asserted-by":"crossref","unstructured":"Elting LS, Escalante CP, Cooksley C. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164(15):1653-1661.","DOI":"10.1001\/archinte.164.15.1653"},{"key":"62076","doi-asserted-by":"crossref","unstructured":"Khorana AA, Francis CW, Culakova E. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3):632-634.","DOI":"10.1111\/j.1538-7836.2007.02374.x"},{"key":"62077","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019; 3(22):3770-3779.","DOI":"10.1182\/bloodadvances.2019000369"},{"key":"62078","doi-asserted-by":"crossref","unstructured":"Prandoni P, Lensing AW, Piccioli A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10):3484-3488.","DOI":"10.1182\/blood-2002-01-0108"},{"key":"62079","doi-asserted-by":"crossref","unstructured":"Liebman HA. Thrombocytopenia in cancer patients. Thromb Res. 2014; 133(Suppl 2):S63-69.","DOI":"10.1016\/S0049-3848(14)50011-4"},{"key":"62080","doi-asserted-by":"crossref","unstructured":"Hsu C, Patell R, Zwicker JI. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv. 2023; 7(17):4721-4727.","DOI":"10.1182\/bloodadvances.2022008644"},{"key":"62081","doi-asserted-by":"crossref","unstructured":"Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):71-79.","DOI":"10.1182\/hematology.2019000369"},{"key":"62082","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow BT, Lee A, Khorana AA. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(6):1246-1249.","DOI":"10.1111\/jth.14015"},{"key":"62083","doi-asserted-by":"crossref","unstructured":"Khanal N, Bociek RG, Chen B. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol. 2016; 91(11):E468-E472.","DOI":"10.1002\/ajh.24526"},{"key":"62084","doi-asserted-by":"crossref","unstructured":"Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol. 2015; 94(2):329-336.","DOI":"10.1007\/s00277-014-2198-6"},{"key":"62085","doi-asserted-by":"crossref","unstructured":"Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019; 30(6):897-907.","DOI":"10.1093\/annonc\/mdz111"},{"key":"62086","doi-asserted-by":"crossref","unstructured":"Raskob GE, van Es N, Verhamme P. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018; 378(7):615-624.","DOI":"10.1056\/NEJMoa1711948"},{"key":"62087","doi-asserted-by":"crossref","unstructured":"Young AM, Marshall A, Thirlwall J. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023.","DOI":"10.1200\/JCO.2018.78.8034"},{"key":"62088","doi-asserted-by":"crossref","unstructured":"McBane RD, Wysokinski WE, Le-Rademacher JG. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost. 2020; 18(2):411-421.","DOI":"10.1111\/jth.14662"},{"key":"62089","doi-asserted-by":"crossref","unstructured":"Agnelli G, Becattini C, Meyer G. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382(17):1599-1607.","DOI":"10.1056\/NEJMoa1915103"},{"key":"62090","doi-asserted-by":"crossref","unstructured":"Hendriks T, McGregor S, Rakesh S. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - the SWAN Study. PLoS One. 2020; 15(6):e0234048.","DOI":"10.1371\/journal.pone.0234048"},{"key":"62091","doi-asserted-by":"crossref","unstructured":"Schulman S, Kearon C, Subcommittee on control of anticoagulation of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005; 3(4):692-694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"62092","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94:496-509.","DOI":"10.1080\/01621459.1999.10474144"},{"key":"62093","doi-asserted-by":"crossref","unstructured":"Campigotto F, Neuberg D, Zwicker JI. Accounting for death as a competing risk in cancer-associated thrombosis studies. Thromb Res. 2012; 129(Suppl 1):S85-87.","DOI":"10.1016\/S0049-3848(12)70023-3"},{"key":"62094","doi-asserted-by":"crossref","unstructured":"Kraaijpoel N, Di Nisio M, Mulder FI. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018; 118(8):1439-1449.","DOI":"10.1055\/s-0038-1667001"},{"key":"62095","doi-asserted-by":"crossref","unstructured":"Monreal M, Falga C, Valdes M. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006; 4(9):1950-1956.","DOI":"10.1111\/j.1538-7836.2006.02082.x"},{"key":"62096","doi-asserted-by":"crossref","unstructured":"Carney BJ, Wang TF, Ren S. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv. 2021; 5(24):5546-5553.","DOI":"10.1182\/bloodadvances.2021005966"},{"key":"62097","doi-asserted-by":"crossref","unstructured":"Sorensen HT, Mellemkjaer L, Olsen JH. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000; 343(25):1846-1850.","DOI":"10.1056\/NEJM200012213432504"},{"key":"62098","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow BR, Lee AYY, Khorana AA. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost. 2018; 2(4):664-669.","DOI":"10.1002\/rth2.12111"},{"key":"62099","doi-asserted-by":"crossref","unstructured":"Samuelson Bannow BT, Walter RB, Gernsheimer TB. Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes. J Thromb Thrombolysis. 2017; 44(4):442-447.","DOI":"10.1007\/s11239-017-1539-4"},{"key":"62100","doi-asserted-by":"crossref","unstructured":"Refaei M, Fernandes B, Brandwein J. Incidence of catheter-related thrombosis in acute leukemia patients: a comparative, retrospective study of the safety of peripherally inserted vs. centrally inserted central venous catheters. Ann Hematol. 2016; 95(12):2057-2064.","DOI":"10.1007\/s00277-016-2798-4"},{"key":"62101","doi-asserted-by":"crossref","unstructured":"Bauchner H, Golub RM, Fontanarosa PB. Reporting and interpretation of randomized clinical trials. JAMA. 2019; 322(8):732-735.","DOI":"10.1001\/jama.2019.12056"},{"key":"62102","doi-asserted-by":"crossref","unstructured":"Kennedy-Martin T, Curtis S, Faries D. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015; 16:495.","DOI":"10.1186\/s13063-015-1023-4"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284192\/76179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284192\/77064","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11317\/76179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:03Z","timestamp":1794045903000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284192","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,19]]}}}